Biotie Therapies - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Biotie Therapies. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Biotie Therapies. The Group's principal activity is the research and development of drugs for dependence disorders, inflammatory diseases, glycomics applications and thrombosis. This is the Group's only segment. The Group's products focus on widespread diseases such as alcohol dependency, rheumatoid arthritis, inflammatory bowel disease, psoriasis, thrombosis and cancer. The Group's 'nalmefene' is the first tablet form drug demonstrating efficacy in reducing heavy drinking in multicenter. Other products include VAP-1 monoclonal which I s an antibody for inflammatory diseases, VAP-1 SSAO is enzyme inhibitor for inflammatory diseases and Integrin 2 B1 is inhibitor for thrombosis. The Group operates in Finland and Germany. The Group acquired CNS and inflammation specialist elbion GmbH in 2008.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report